ROSA MARÍA
AYALA DÍAZ
Profesora titular de universidad
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (10)
2022
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
2021
-
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens
Scientific Reports, Vol. 11, Núm. 1
2019
-
A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
Haematologica, Vol. 104, Núm. 2, pp. 288-296
2018
-
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
Haematologica
-
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology
British Journal of Haematology
2014
-
Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
Blood, Vol. 123, Núm. 20, pp. 3073-3079
2013
-
Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma: Results from a GEM/PETHEMA study
British Journal of Haematology, Vol. 163, Núm. 5, pp. 581-589
2008
-
Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: The prognostic impact of achieving molecular response
British Journal of Haematology, Vol. 142, Núm. 5, pp. 766-774